Navigation Links
Prescription drug could boost effects of vaccines for HIV and other diseases
Date:5/5/2010

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

John Pesce and colleagues at the Naval Medical Research Center and UC-Berkeley note that vaccines prepared from weakened or inactivated viruses or bacteria have had enormous success in preventing polio, influenza, and other diseases. However, vaccines containing living or weakened viruses cannot be used for HIV, hepatitis C, and other devastating diseases due to safety concerns. Scientists are instead trying to develop a new generation of vaccines, made with DNA or proteins from infectious agents that can prevent illness without carrying a risk of causing the diseases. These vaccines will be weaker than conventional vaccines and require a new generation of "adjuvants," ingredients that boost a vaccine's immunogenicity.

The report identifies a promising candidate in the form of imiquimod, an immune-boosting drug already in general use. The scientists coated imiquimod with dextran-based microparticles in hopes of increasing the efficiency of cellular uptake by cells associated with immune response initiation. Sure enough, the coated drug significantly boosted levels of inflammatory cytokines in laboratory cultures of immune cells from mice. The findings have "broad significance" and open the door to more extensive testing of the approach, they indicate.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert  

Page: 1

Related biology news :

1. Fancier fakes: Makers of bogus prescription drugs pose new challenges
2. Some prescription meds can harm fetus
3. MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse
4. MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse
5. Physical activity and health: Finding the right prescription
6. Trends in prescription medication sharing among reproductive-aged women
7. Roots meshed in waste materials could clean dirty water
8. Bionic coating could help ships to economize on fuel
9. Glaucomas unique protein expression could enhance diagnosis and treatment
10. Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol
11. Olive oil could guard against developing ulcerative colitis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Prescription drug could boost effects of vaccines for HIV and other diseases
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... bird flu virus H5N1 emerged in late 2005 and replaced ... southern China, despite an ongoing program to vaccinate poultry, according ... with scientists at St. Jude Children's Research Hospital. , The ... the increased occurrence of H5N1 poultry infections since October 2005, ...
... first large-scale analysis of proteins in the brains of ... and mechanisms that may one day lead to new ... in the current issue of Molecular Psychiatry, released on-line ... and point to profound changes in brain function related ...
... immune response to the 1918 influenza virus provides new ... in an article appearing online today in the journal ... 1918 virus triggers a hyperactive immune response that may ... their results suggest that it is the combination of ...
Cached Biology News:Control measures fail to stop spread of new H5N1 virus 2High-tech research shows cocaine changes proteins and brain function 2Mouse study reveals new clues about virulence of 1918 influenza virus 2Mouse study reveals new clues about virulence of 1918 influenza virus 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... of Compensatory Award Will Now Proceed -, MADISON, N.J., ... its motion for judgment as a matter of law on ... Scroggin v.,Wyeth, in the U.S. District Court, Eastern District of ... punitive damages award of,$19,360,000 rendered by the Little Rock jury ...
... USA Study to Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ... of the XIENCE V(TM) USA post-approval study, with six,hospital centers already ... Drug Administration approved the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The ...
... 10 most promising drugs ... TSX Exchange Symbol: ... the "Company") (TSX:RVX) novel lead ApoA-I drug,candidate, RVX-208 has been ... (CVD) drugs available for strategic partnering by an,independent committee assembled ...
Cached Biology Technology:Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4Industry Leaders Select Resverlogix's RVX-208 2Industry Leaders Select Resverlogix's RVX-208 3
... EA. Ultrospec 6300 pro UV/Visible ... the Pharmacopoeia in terms of instrument specification ... being able to be used for rapid, ... excellent scanning capability., *Press to read high ...
... Cy3 Ab Labeling Kit, 1 kit. ... with CyDye fluorescent dyes. Conjugations are ... complete within 1 h. Dyes are ... to ensure consistent labelings. Category: Blotting ...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Biology Products: